Global Contract Development and Manufacturing Organization (CDMO) Outsourcing Market

Contract Development And Manufacturing Organization (CDMO) Outsourcing Market Size, Share, Growth Analysis, By СМО (API Manufacturing, Finished Product Manufacturing), By CRO (Early Phase Development Services, Clinical), By Region - Industry Forecast 2026-2033

Report ID: SQSG35J2008 | Region: Global | Published Date: January, 2025
Pages: 283 |Tables: 35 |Figures: 74

To request a free sample copy of this report, please complete the form below.

Our Clients

  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt

    • FAQs

    Global Contract Development And Manufacturing Organization USD 243.26 Billion in 2024 Outsourcing Market size was valued at USD 258.83 Billion in 2025 and is poised to grow from USD 425.16 Billion by 2033 to 6.4%, growing at a CAGR of (2026–2033) during the forecast period (2025-2032). 

    Global contract development and manufacturing organization (CDMO) outsourcing market is relatively fragmented, with a high level of competition. The prominent players operating in the market are constantly adopting various growth strategies to stay afloat in the market. Product launches, innovations, mergers, and acquisitions, collaborations and partnerships, and intensive R&D are some of the growth strategies that are adopted by these key players to thrive in the competitive market. The key market players are also constantly focused on R&D to supply industries with the most efficient and cost-effective solutions. 'Lonza Group (Switzerland) ', 'Catalent (United States) ', 'WuXi Biologics (China) ', 'Samsung Biologics (South Korea) ', 'Siegfried Holding AG (Switzerland) ', 'Fujifilm Diosynth Biotechnologies (Japan) ', 'Recipharm AB (Sweden) ', 'Boehringer Ingelheim (Germany) ', 'MilliporeSigma (United States) ', 'Aenova Group (Germany) ', 'Fareva (France) ', 'Laurus Labs (India) ', 'Delpharm (France) ', 'Piramal Pharma Solutions (India) ', 'Almac Group (United Kingdom) ', 'Evonik Industries (Germany) ', 'Cambrex Corporation (United States) ', 'Lonza Group (Switzerland) ', 'Patheon (United States) ', 'WuXi AppTec (China) '

    Owing to expanding acceptance of a westernized lifestyle, rising economic development, and rising population, the burden of chronic illnesses is rising significantly over the world. About 133 million Americans suffer from chronic illnesses, accounting for more than 40% of the nation's population and being typically incurable and continuous. It is anticipated that by 2020, there would be 157 million people worldwide, 81 million of whom will have various illnesses. Around 8% of children aged 5 to 17 reported having limited activities because of at least one chronic illness or impairment, while around 50% of adults report having a chronic condition.

    Currently, the contract development and manufacturing organization outsourcing market is fragmented. The necessity for quick innovations to provide efficient process solutions to improve the drug development process has increased among pharmaceutical businesses. Many contract development and manufacturing businesses are preferring to combine with small and major pharma & biotech enterprises, along with many life-science corporations, in order to improve their service offerings.

    The market in North America is distinguished by the region's long-standing CDMO presence. Along with this element, expanding partnerships between pharmaceutical firms and CDMOs providing a wide variety of services are to blame for the region's leading market share globally. The pharmaceutical business is supported by an estimated 300 pharmaceutical contract development and manufacturing companies (CDMOs). The industry is still incredibly fragmented despite rising merger and acquisition (M&A) activity; the top five CDMOs account for only 15% of the market as a whole.

    Related Reports

    Regulatory Affairs Outsourcing Market
    Buy Now GET FREE SAMPLE
    Procurement Outsourcing Market
    Buy Now GET FREE SAMPLE
    Engineering Services Outsourcing Market
    Buy Now GET FREE SAMPLE
    Business Process Outsourcing Market
    Buy Now GET FREE SAMPLE
    Contract Research Organization Market
    Buy Now GET FREE SAMPLE
    Medical Affairs Outsourcing Market
    Buy Now GET FREE SAMPLE
    Knowledge Process Outsourcing Market
    Buy Now GET FREE SAMPLE
    Healthcare IT Outsourcing Market
    Buy Now GET FREE SAMPLE

    Feedback From Our Clients

    Global Contract Development and Manufacturing Organization (CDMO) Outsourcing Market

    Report ID: SQSG35J2008

    $5,300
    BUY NOW